Video Experimental Relacionado

Updated: Jun 17, 2026

A Cell Culture Model of Resistance Arteries

A Cell Culture Model of Resistance Arteries

Published on: September 8, 2017

Diferentes efectos de los estrógenos y la progesterona en la expresión génica de los receptores de ATP en las células

G Nickenig¹, K Strehlow, S Wassmann

¹Klinik III für Innere Medizin, Universität zu Köln, Cologne, Germany. georg.nickenig@uni-koeln.de

|October 12, 2000

Resumen

El estrógeno y la progesterona tienen efectos opuestos en el receptor de la angiotensina II (AT1) en las células vasculares. El estrógeno disminuye la expresión de los receptores AT{1}, mientras que la progesterona la aumenta, lo que afecta el riesgo de enfermedades cardiovasculares.

Área de la Ciencia:

Endocrinología Endocrinología.
Biología Cardiovascular Biología Cardiovascular
Biología Molecular Biología Molecular

Sus antecedentes:

Los efectos vasoprotectores de la terapia con estrógenos posmenopáusicos pueden verse obstaculizados por las progestinas.
Efectos diferenciales investigados de los estrógenos y la progesterona en la expresión génica del receptor AT(1) en las células musculares lisas vasculares (VSMC).

Objetivo del estudio:

Para dilucidar los distintos impactos de los estrógenos y la progesterona en la expresión de los receptores AT{1} en VSMCs.
Para entender los mecanismos moleculares subyacentes a estos efectos diferenciales.

Principales métodos:

Análisis del norte y el bloqueo del oeste para evaluar los niveles de ARNm y proteínas de los receptores AT{1}.
Ensayos de ejecución nuclear para determinar las tasas de transcripción.
Estudios de la vida media del ARNm.
La inhibición farmacológica de las vías de señalización (por ejemplo, óxido nítrico, PI3−kinasa).

Principales resultados:

17beta-estradiol regulado a la baja AT(1) receptor de ARNm y proteínas.
La progesterona aumentó significativamente la regulación del ARNm y la proteína de los receptores AT(1) del receptor.
El efecto del estrógeno involucró a los receptores de estrógeno y las vías del óxido nítrico.
El efecto de la progesterona implicó la activación de la PI(3)-cinasa y la mejora de la transcripción y la estabilidad del ARNm.
El estrógeno inhibió la producción de especies reactivas de oxígeno; la progesterona la mejoró.

Conclusiones:

La regulación diferencial del receptor AT(1) por el estrógeno y la progesterona influye en la patogénesis de las enfermedades cardiovasculares.
Estos efectos hormonales opuestos pueden explicar los impactos contrarios en la incidencia de enfermedades cardiovasculares posmenopáusicas.

Más Videos Relacionados

Using In Vivo and Tissue and Cell Explant Approaches to Study the Morphogenesis and Pathogenesis of the Embryonic and Perinatal Aorta

Using In Vivo and Tissue and Cell Explant Approaches to Study the Morphogenesis and Pathogenesis of the Embryonic and Perinatal Aorta

Published on: September 12, 2017

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Published on: February 15, 2022

Videos de Conceptos Relacionados

Multiple Allele Traits

Multiple Allele Traits

The Concept of Multiple Allelism

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...